Ketamine

By Anonymous This morning my little cousin sent me an article on a company that is making 5-MeO DMT for use in mental health conditions (see article below). I found this even more interesting than I typically would have as I smoked this medicine two days ago, for the first time. I decided to do […]

A recent article by Calder et al. 2022, highlights in detail how classic psychedelics such as psilocybin, LSD and DMT enhance and sustain neuroplasticity and neurogenesis, the growth of new neural connections in the brain. The article analyzes which parts of the brain are most likely to be affected by neurogenesis and possible clinical ramifications

After years of treating patients with Ketamine, one of the most satisfying experiences we have seen has been witnessing the client’s return to functioning. Mental conditions such as depression, PTSD, severe anxiety, etc… can be debilitating and are a huge cause of disability worldwide. In fact, it is well known that mental illness is responsible

In 2021, investors poured a whopping $708 Million into the psychedelic medicine space. As 2022 goes on, even more psychedelic-focused startups are receiving the attention of major investors. So – what’s all the hype about? Ketamine got its start in the 1960s and 1970s as an anesthetic. Now, decades later, ketamine is being heralded as

At its Tuesday meeting (6 September 2022), the San Francisco Board of Supervisors passed a resolution that initiates the decriminalization of psychedelics like psilocybin, the active component of magic mushrooms. The resolution passed unanimously, and also applies to several other psychedelic compounds. The Board of Supervisors calls for the regulation of certain psychedelic compounds to

Is ketamine addictive? Is it habit forming? Is it abusable? What will happen if I treat a client with ketamine who suffers from either an active or stable history of substance use disorder? These are some of the leading questions that are being investigated with regards to ketamine’s ability to treat clients with these conditions.

As the psychedelic renaissance continues, research is constantly evolving and revealing the powerful therapeutic potential of these medications. A recent study from New York University looked at the potential for psilocybin, the active ingredient in “magic mushrooms”, to alleviate problem drinking. So far, the evidence is encouraging. This is what the study looked at: 93

At Skylight Psychedelics, we recognize that the era of psychedelic medicine is here, and with it comes new hope for people struggling with depression, trauma from PTSD, anxiety and addiction. Hobbled for decades by draconian federal regulations, psychedelic medicines like ketamine, psilocybin, MDMA, LSD, DMT, mescaline, ayahuasca and iboga are becoming increasingly recognized by the

Depression and PTSD are some of the most debilitating public health problems we currently face. Depression affects men, women, adults, adolescents and children, and the estimated annual cost of depression is over $2 Billion per year. People who suffer from depression endure persistent feelings of hopelessness, fatigue, lack of the ability to enjoy life, poor